ClariMed Inc. Enhances Services through We Are Human Acquisition
ClariMed Inc. Expands Growth Through Strategic Acquisition
ClariMed, Inc., recognized as a leader in the realm of human-centered medical device development, has taken a significant step forward in its mission. The company has successfully acquired We Are Human, a consultancy rooted in user-focused design and research within the MedTech arena. This acquisition serves to broaden ClariMed's geographical influence into new markets, particularly the Southeast region of the United States.
We Are Human's Expertise Bolsters ClariMed's Offerings
With the inclusion of We Are Human's expert team and their state-of-the-art usability lab, ClariMed is now better equipped to cater to its client base. Annmarie Nicolson, the founder of We Are Human, has been appointed as Principal, bringing a wealth of knowledge in formative research, contextual inquiries, and user experience (UX) research tailored for MedTech innovation. This strategic integration is set to enhance ClariMed's overall service offering, reinforcing its human-centered approach to medical technologies.
Strengthening Capabilities and Values
Kelley Kendle, the CEO of ClariMed, emphasized the importance of this acquisition, stating, "This acquisition represents our continued commitment to our user-centered foundation while expanding our reach and strengthening our capabilities. Regional variability allows us to better address our patients' needs and advance our mission to make medical technology safer and more impactful for those who need it most. This isn't just a merger of capabilities — it's a deep alignment of values."
Enhancing User Experience Research
The acquisition further establishes ClariMed as a pivotal partner in the medical device services industry. By integrating We Are Human's specialized knowledge in user experience research, regulatory compliance, and design validation, ClariMed can now better meet the needs of both its US and international clients. The We Are Human team brings vital ISO 13485 certification along with extensive experience meeting IEC-62366 and FDA Guidance requirements.
A New Research Facility in the Southeast
The Atlanta laboratory, now part of ClariMed's network, will allow the company to tap into diverse participant populations for user research and usability testing. This strategic move not only complements ClariMed’s existing locations such as Chadds Ford, PA, and Cambridge MA, but also emphasizes the company’s commitment to expanding its footprint to address specific market needs.
Commitment to Human-Centered Solutions
This acquisition aligns seamlessly with ClariMed's growth strategy, dedicated to offering comprehensive, human-centered solutions in the medical device domain. By uniting the strengths of both organizations, ClariMed positions itself to cater effectively to pharmaceutical and medical device manufacturers aiming to accelerate their time to market while prioritizing patient safety and improving user experience.
About ClariMed
ClariMed stands as a pioneer in human-centered development and regulatory practices for medical products that pharmaceutical and medical device manufacturers produce. The firm is committed to fostering innovation while ensuring the safe and effective application of medical products. With a firm presence across the U.S. and the United Kingdom, ClariMed offers integrated solutions that prioritize human factors at every stage of device development and regulatory processes.
About We Are Human
Established in 2020, We Are Human operates as an ISO 13485 certified consultancy specializing in Human Factors, User Research, and UX design. The agency believes that the core of innovation lies in understanding human needs, and strives to enhance health and wellbeing through effective product development across various sectors, including MedTech and digital health.
Frequently Asked Questions
What is the significance of ClariMed's acquisition of We Are Human?
This acquisition significantly enhances ClariMed's user-centered approach in the medical device market, expanding its geographical reach and improving service offerings.
What expertise does Annmarie Nicolson bring to ClariMed?
Annmarie Nicolson brings extensive experience in user-centered design and research, which will be crucial in guiding ClariMed's strategic direction post-acquisition.
How will the acquisition impact ClariMed's operations?
The acquisition allows ClariMed to access new talent pools and diverse participant populations, thereby strengthening its user experience research and usability testing capabilities.
What is ClariMed's mission following this acquisition?
ClariMed aims to continue delivering human-centered medical technologies globally, enhancing patient safety and improving user experience across its product offerings.
Where is ClariMed's newest research facility located?
The latest addition to ClariMed's research facilities is in Atlanta, serving as a hub for user research and usability testing in the Southeast.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.